Why Revvity (RVTY) Stock Is Up Today
Revvity (NYSE: RVTY) shares rose about 3% after the company reported Q2 2026 adjusted EPS of $1.41 versus $1.21 expected, and revenue of $729.68 million versus $703.39 million. Revvity lifted full-year guidance to 4% to 5% organic growth and EPS of $5.30 to $5.40. Stifel raised its target to $110 and Bernstein to $120.
How this was made
The 30-second read
Why it matters
Q2 beat plus raised full-year organic growth and EPS range is a direct catalyst for repricing, reflected in the afternoon +3.1% move and subsequent cooling to +2.6%.
Market read
This is a same-day earnings and guidance catalyst for RVTY, with analyst target increases reinforcing the positive market reaction.
What to watch
The article does not quantify margin, cash flow, or segment profitability; traders may reprice on quality of earnings rather than top-line/organic growth alone.
Background
Revvity is a life sciences company with Diagnostics and Life Science segments; prior quarter guidance was described as cautious in the article’s recap.
Ticker impact
Revvity reported Q2 2026 adjusted EPS of $1.41 and revenue of $729.68M, beating estimates and lifting full-year guidance.
Bullish bias for the next few sessions, with potential for profit-taking given the stock’s proximity to the 52-week high.
The article cites a same-day +3.1% move tied directly to the EPS/revenue beat and raised FY organic growth and EPS range, plus analyst target increases.
Market effects
Positive read-through for life sciences tools and diagnostics demand expectations, though the article is single-company focused.
No specific regional effects mentioned beyond US-listed trading reaction.
No explicit global macro or international regulatory drivers cited.
Counterpoint
The stock’s move may fade if investors focus on the magnitude of the raised guidance versus prior expectations, especially with shares near the 52-week high.
Key entities
- companyRevvity
Reported Q2 2026 adjusted EPS of $1.41 and revenue of $729.68M, and raised full-year guidance to 4-5% organic growth and EPS $5.30-$5.40.
- analyst_firmStifel
Raised its price target to $110 from $100 after the results.
- analyst_firmBernstein
Increased its target to $120 from $115 following the results.
